{
    "nct_id": "NCT05578326",
    "official_title": "Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer",
    "inclusion_criteria": "* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n* Age â‰¥ 18 years at the time of consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Measurable disease according to RECIST v1.1 within 28 days prior to start of treatment.\n* Previous treatment with a platinum agent, PD1 or PDL1 agent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active infection requiring systemic therapy.\n\n  * Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n  * Treatment with any investigational drug within 4 weeks prior to start of treatment.\n  * A known allergy or sensitivity to either study drug or its excipients.\n  * Subject is receiving prohibited medications or treatments as listed in the protocol.",
    "miscellaneous_criteria": "In order to participate in this study, a subject must meet all of the eligibility criteria outlined below."
}